Cancer drug prices cut by up to 96.45% — 1,364 formulations revised, ₹3,540 crore saved
Synopsis
Prices of 1,364 anti-cancer drug formulations have been slashed — some by as much as 96.45% — after the NPPA capped trade margins on 137 oncology drugs. The move is projected to save Indian patients ₹3,540 crore a year, covering immunotherapy drugs, Bevacizumab, Denosumab, and Pegfilgrastim, effective 9 November 2026.
Key Takeaways
Revised MRPs for 1,364 anti-cancer formulations came into effect on 9 November 2026 .
Annual consumer savings estimated at ₹3,540.38 crore following trade margin caps on 137 drugs .
679 brands reported price cuts of more than 50% ; the highest single reduction was 96.45% .
85 pharmaceutical companies covering 121 drugs have submitted revised MRPs as of 8 November .
Drugs covered include immunotherapy agents for 20+ cancer types , Denosumab , Pegfilgrastim , and Bevacizumab .
Consumers can verify prices via the Pharma Sahi Daam app or report overcharging at the NPPA helpline 1800-111-255 .
Revised prices of 1,364 anti-cancer drug formulations came into effect on 9 November 2026, with the government estimating annual consumer savings of ₹3,540.38 crore following a cap on trade margins for 137 anti-cancer drugs. The price rationalisation, driven by the National Pharmaceutical Pricing Authority (NPPA), marks one of the most sweeping oncology affordability interventions in recent years.
What Changed and When
The NPPA, functioning under the Department of Pharmaceuticals, capped trade margins on the maximum retail price (MRP) of 137 anti-cancer drugs based on recommendations from an expert committee constituted by the Directorate General of Health Services on 17 October 2026. As of 8 November, 85 pharmaceutical companies had reported revised MRPs for 1,364 formulations covering 121 drugs, according to the Ministry of Chemicals and Fertilizers.
Scale of Price Reductions
Of the 1,364 formulations, 679 brands reported price reductions of more than 50%. The steepest single cut stood at 96.45% — effectively rendering certain drugs a fraction of their earlier cost. This follows an earlier NPPA release in October 2026 that covered revised MRPs for more than 500 brands of anti-cancer medicines under the same trade margin rationalisation drive.
Which Drugs Are Covered
The revised pricing covers a broad oncology portfolio. Immunotherapy drugs prescribed for more than 20 types of cancer are included, as is Denosumab — used in the treatment of breast and prostate cancer — Pegfilgrastim for the prevention of neutropenia among cancer patients, and Bevacizumab, approved for the treatment of colon, ovarian and cervical cancers, according to the government.
How Consumers Can Verify Prices
Consumers can check the revised MRPs printed on medicine packs and verify prices through the Pharma Sahi Daam mobile application or the NPPA website. No chemist or hospital pharmacy is permitted to charge above the revised MRP. Complaints regarding overcharging or other pricing-related issues can be registered through the Pharma Jan Samadhan portal or by contacting the NPPA helpline at 1800-111-255.
Policy Context and What Comes Next
The initiative is aimed at curbing excessive trade margins across the pharmaceutical supply chain — a persistent concern in India's oncology market, where high retailer and distributor markups have historically inflated patient costs well beyond manufacturer prices. This is not the first such exercise: the NPPA has previously rationalised trade margins on cardiovascular and anti-diabetic drugs, but the scale of this oncology push — in both drug count and projected savings — is notably larger. With revised MRPs now effective, enforcement at the pharmacy and hospital level will be the critical next step.
Point of View
540 crore savings figure is significant, but it is a projection, not a guarantee; enforcement at hospital pharmacies, where markups have historically been most aggressive, will determine whether patients actually see the benefit. The 96.45% reduction on a single drug is striking, but it also reveals how distorted pricing was to begin with — a discomfort the industry has yet to publicly address.
NationPress
9 Nov 2026
Frequently Asked Questions
What is the NPPA cancer drug price cut announced in November 2026?
The NPPA capped trade margins on 137 anti-cancer drugs, bringing revised MRPs for 1,364 formulations into effect on 9 November 2026. The government estimates annual consumer savings of ₹3,540.38 crore as a result.
By how much have cancer drug prices been reduced?
679 of the 1,364 revised formulations saw price reductions of more than 50%, with the highest single reduction standing at 96.45%. The cuts apply to MRPs across 85 pharmaceutical companies.
Which cancer drugs are included in the revised pricing?
The revised MRPs cover immunotherapy drugs prescribed for over 20 types of cancer, Denosumab for breast and prostate cancer, Pegfilgrastim for neutropenia prevention, and Bevacizumab for colon, ovarian and cervical cancers, among others.
How can patients verify the new cancer drug prices?
Consumers can check revised MRPs printed on medicine packs, use the Pharma Sahi Daam mobile application, or visit the NPPA website. No chemist or hospital pharmacy is permitted to charge above the revised MRP.
What should a patient do if overcharged for cancer medicine?
Patients can register a complaint on the Pharma Jan Samadhan portal or call the NPPA helpline at 1800-111-255 to report overcharging or pricing-related violations.
